Investors received a note on Tuesday that changed the rating from 'hold' to'sell'.
Omeros Price Performance
The stock fell $0.23 in mid-day trading Tuesday to $5.18. The stock changed hands 416,857 times, as opposed to the average of 790763. The company's debt-to equity ratio is 4.03; its quick ratio is 3.00, and its current ratio is 3.00. The company has a $325.46-million market cap, a P/E ratio of 7,00 and a beta value of 1.01. The 50-day moving average of the company is $5.88, and its 200 day moving average is $4.65. The last time ) released its quarterly results was on May 9th. The biopharmaceutical firm reported ($0.63) in earnings per share for the third quarter, falling short of the consensus estimate ($0.55) ($0.08). Analysts at equities firms expect Omeros to post a -2.15 per-share profit for the current fiscal year.
Insider Buying & Selling
Other Omeros news: Director Arnold C. Hanish has sold 5,000 shares in the company on Monday, 22nd May. The stock was bought at an average of $6.46 for a value of $32,300.00. After the transaction, the Director now owns 35 067 shares of stock in the company, valued at $226 532.82. Insiders own 10.90% currently.
Institutional Trading of Omeros
Recently, several institutional investors and hedge fund have bought and sold the stock. Charles Schwab Investment Management Inc. increased its stake in Omeros in the fourth-quarter by 1.4%. Charles Schwab Investment Management Inc. owns 312 409 shares of stock in the biopharmaceutical firm valued at $706,000. This is after purchasing 4,170 additional shares during the previous quarter. Bank of New York Mellon Corp increased its stake in Omeros shares by 3.0% during the first quarter. Bank of New York Mellon Corp owns 205.160 shares of biopharmaceutical stock worth $1,233,000, after buying an additional 5,938 during the last quarter. HighTower Advisors LLC increased its holdings of Omeros in the first quarter by 11.5%. HighTower Advisors LLC owns 58.339 shares worth $273,000 of the biopharmaceutical firm's stock after buying an additional 6,000 in the last quarter. Geode Capital Management LLC increased the size of its Omeros position by 1.2% in the fourth quarter. Geode Capital Management LLC owns 605,812 of the biopharmaceutical firm's shares worth $1,369,000. This is after purchasing an additional 7,263 during the fourth quarter. Swiss National Bank increased its holdings of Omeros during the first three months by 7.3%. Swiss National Bank owns now 140,500 shares worth $844,000 of the biopharmaceutical firm's stock after purchasing an additional 9,600 in the last quarter. Institutional investors and hedge fund own 31.53% the company's shares.
Omeros Company Profile
Get Free Report
Omeros Corporation is a biopharmaceutical clinical-stage company that discovers, develops and commercializes small molecule and protein therapeutics and orphan indications for inflammation, complement-mediated disease, cancers and addictive and compulsive disorder. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
MarketBeat.com offers a FREE daily email newsletter